Three months ago at ASCO, Loxo Oncology wowed the crowd at the big cancer conference with some early-stage data for its second genetically targeted cancer drug candidate. Today, the biotech announced that the FDA seems similarly impressed, offering a breakthrough drug designation to shorten the regulatory timeline just as Loxo has hoped.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,